Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI119820

Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

H Wennbo, M Gebre-Medhin, A Gritli-Linde, C Ohlsson, O G Isaksson, and J Törnell

Department of Physiology, Research Centre for Endocrinology and Metabolism, Göteborg University Medicinaregatan 1F S-413 90 Göteborg, Sweden.

Find articles by Wennbo, H. in: PubMed | Google Scholar

Department of Physiology, Research Centre for Endocrinology and Metabolism, Göteborg University Medicinaregatan 1F S-413 90 Göteborg, Sweden.

Find articles by Gebre-Medhin, M. in: PubMed | Google Scholar

Department of Physiology, Research Centre for Endocrinology and Metabolism, Göteborg University Medicinaregatan 1F S-413 90 Göteborg, Sweden.

Find articles by Gritli-Linde, A. in: PubMed | Google Scholar

Department of Physiology, Research Centre for Endocrinology and Metabolism, Göteborg University Medicinaregatan 1F S-413 90 Göteborg, Sweden.

Find articles by Ohlsson, C. in: PubMed | Google Scholar

Department of Physiology, Research Centre for Endocrinology and Metabolism, Göteborg University Medicinaregatan 1F S-413 90 Göteborg, Sweden.

Find articles by Isaksson, O. in: PubMed | Google Scholar

Department of Physiology, Research Centre for Endocrinology and Metabolism, Göteborg University Medicinaregatan 1F S-413 90 Göteborg, Sweden.

Find articles by Törnell, J. in: PubMed | Google Scholar

Published December 1, 1997 - More info

Published in Volume 100, Issue 11 on December 1, 1997
J Clin Invest. 1997;100(11):2744–2751. https://doi.org/10.1172/JCI119820.
© 1997 The American Society for Clinical Investigation
Published December 1, 1997 - Version history
View PDF
Abstract

Transgenic mice overexpressing the human growth hormone gene develop mammary carcinomas. Since human growth hormone gene can activate both the growth hormone receptor (GHR) and the prolactin (PRL) receptor (PRLR), it is not clear which receptor system is responsible for the malignant transformation. To clarify the receptor specificity, we created transgenic mice with two different genes: (a) transgenic mice overexpressing the bovine growth hormone (bGH) gene having high levels of bGH only activating the GHR and also high serum levels of IGF-I; and (b) transgenic mice overexpressing the rat PRL (rPRL) gene that have elevated levels of PRL (one line 150 ng/ml and one line 13 ng/ml) only binding to the PRLR and with normal IGF-I levels. When analyzed histologically, all of the PRL transgenic female mice developed mammary carcinomas at 11-15 mo of age. Only normal mammary tissue was observed among the bGH transgenic animals and the controls. Cell lines established from a tumor produced rPRL and expressed PRLR. In organ culture experiments, an auto/paracrine effect of rPRL was demonstrated. In conclusion, activation of the PRLR is sufficient for induction of mammary carcinomas in mice, while activation of the GHR is not sufficient for mammary tumor formation.

Version history
  • Version 1 (December 1, 1997): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts